Pfizer’s planned $43 billion acquisition of Seagen will be a major test for the Federal Trade Commission since the monopoly-regulating agency revised its views of what constitutes anti-competitive behavior in the pharmaceutical industry. The buyout, which the companies expect to close later this year or early next, will substantially expand Pfizer’s presence in cancer treatment, where it already has 16 targeted drugs along with older chemotherapies. With Seagen, it will gain four more marketed cancer drugs, and add an additional 12 experimental medicines that are in human testing.
Read the full article: In Pfizer-Seagen Review, FTC Has Chance to Set New Pharma Precedent //
Source: https://www.biopharmadive.com/news/pfizer-seagen-ftc-antitrust-review-competition/630298